Assembling evidence grade
Loading
Independent evidence before payment.
Long-acting amylin analogue · also: AM833
Cagrilintide carries an Evidence Grade of B (High confidence). The strongest published evidence catalogued is human rct / review.
Grade B rule: One human RCT, Phase-2-only RCTs, or three or more other human studies.
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
Human-use stop
This compound is investigational, warned or not approved for human use. A seller calling it “research only,” showing testimonials, registering a company or publishing a COA does not create an approved consumer medicine. Seller links below are market-surveillance records, not recommendations.
Cagrilintide is a long-acting amylin analogue studied alone and in combination with semaglutide in registered trials.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: there are 6 randomised human trials here — the strongest kind of evidence. That is about the research, not about any particular seller or batch.
Strongest: randomised or pooled human trials.
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. The lancet. Diabetes & endocrinology, 2026.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine, 2025.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2025.
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (Clinical research ed.), 2024.
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (London, England), 2023.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England), 2021.
Observational, open-label or small human studies.
none catalogued
Preclinical animal models — not a human outcome.
none catalogued
Cell / tissue studies — not a human outcome.
none catalogued
Proposed mechanism — hypothesis, not evidence of effect.
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocrine reviews, 2026.
Weight management treatment in obesity. Medicina clinica, 2025.
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in review, 2024.
Amylin analogs for the treatment of obesity without diabetes: present and future. Expert review of clinical pharmacology, 2024.
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian journal of endocrinology and metabolism, 2024.
Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of medicinal chemistry, 2021.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
Investigational; combination products are not approved. Evidence is early and concerns specific supervised formulations.
An investigational drug studied in trials but with no approved formulation in major markets. There is no legal consumer route; anything sold is unapproved material of unverified identity, purity and dose.
PepCred flags any vendor selling this compound to the public as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
Sample of 8 (not ranked) — see all on ClinicalTrials.gov:
No FDA-approved (US) drug labelling found for this compound. A search of openFDA returned no approved product containing it as an active ingredient.
This reflects US FDA approval only — other regulators (e.g. MHRA, EMA) may differ; see the note below. Absence of an approved label is not, by itself, a safety finding, and a “research use only” label does not establish safety, legality or correct identity.
PepCred note: Investigational — no marketing authorisation.
These unranked records show where the name was detected. For an investigational, warned or unapproved compound, no seller, company registration, review score or COA creates an approved human-use route.
None of these is verified for human use.